Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

BACKGROUND: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Therap Adv Gastroenterol
Main Authors: Massimi, Davide, Barberio, Brigida, Bertani, Lorenzo, Costa, Francesco, Ferronato, Antonio, Facchin, Sonia, Cardin, Romilda, Cingolani, Linda, Casadei, Cesare, D’Incà, Renata, Zingone, Fabiana, Savarino, Edoardo Vincenzo
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2021
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239954/
https://ncbi.nlm.nih.gov/pubmed/34249147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211023384
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares